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Abstract
Introduction: Response to antiretroviral therapy (ART) among individuals infected with HIV-2 is poorly described. We compared
the immunological response among patients treated with three nucleoside reverse-transcriptase inhibitors (NRTIs) to boosted
protease inhibitor (PI) and unboosted PI-based regimens in West Africa.
Methods: This prospective cohort study enrolled treatment-naı¨ve HIV-2-infected patients within the International Epidemio-
logical Databases to Evaluate AIDS collaboration in West Africa. We used mixed models to compare the CD4 count response to
treatment over 12 months between regimens.
Results: Of 422 HIV-2-infected patients, 285 (67.5%) were treated with a boosted PI-based regimen, 104 (24.6%) with an
unboosted PI-based regimen and 33 (7.8%) with three NRTIs. Treatment groups were comparable with regard to gender (54.5%
female) and median age at ART initiation (45.3 years; interquartile range 38.3 to 51.8). Treatment groups differed by clinical stage
(21.2%, 16.8% and 17.3% at CDC Stage C or World Health Organization Stage IV for the triple NRTI, boosted PI and unboosted PI
groups, respectively, p0.02), median length of follow-up (12.9, 17.7 and 44.0 months for the triple NRTI, the boosted PI and the
unboosted PI groups, respectively, pB0.001) and baseline median CD4 count (192, 173 and 129 cells/ml in the triple NRTI, the
boosted PI and the unboosted PI-based regimen groups, respectively, p0.003). CD4 count recovery at 12 months was higher
for patients treated with boosted PI-based regimens than those treated with three NRTIs or with unboosted PI-based regimens
(191 cells/ml, 95% CI 142 to 241; 110 cells/ml, 95% CI 29 to 192; 133 cells/ml, 95% CI 80 to 186, respectively, p0.004).
Conclusions: In this observational study using African data, boosted PI-containing regimens had better immunological response
compared to triple NRTI combinations and unboosted PI-based regimens at 12 months. A randomized clinical trial is still
required to determine the best initial regimen for treating HIV-2 infected patients.
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Introduction
Between one and two million people are estimated to be
living with HIV-2 infection in West Africa [1], the region that
is the epicentre of the HIV-2 epidemic, with prevalence
apparently decreasing over time [25]. Although there is
limited experience in the management of HIV-2 infection
worldwide, it is well known that HIV-2 is naturally resistant to
the non-nucleoside reverse-transcriptase inhibitors (NNRTIs)
[6,7] that have been part of the standard first-line antire-
troviral therapy (ART) for the treatment of HIV-1 infection in
low-income countries for the past decade. In the 2010 treat-
ment guidelines [8], the World Health Organization (WHO)
recommended treating patients living with HIV-2 in limited-
resource countries with an ART regimen containing a
ritonavir-boosted protease inhibitor (PI) plus two nucleoside
reverse-transcriptase inhibitors (NRTIs). Triple NRTI regimens
were recommended only in patients with CD4 counts 200
cells/mm3. In the 2013 guidelines [9],WHO recommendations
proposed a regimen containing three NRTIs or a ritonavir-
boosted PI plus two NRTIs. If a PI-based regimen is used, the
preferred option for first-line PI is lopinavir. However, this
recommendation is based on weak evidence according to
WHO grading criteria [811]. Although PIs are active against
HIV-2, they show varying degrees of activity due to natural
protease polymorphisms. A study that compared the potency
of different PIs against HIV-2 showed that lopinavir, saquinavir,
tipranavir and darunavir were the most potent [10]. Another
study reported that saquinavir, lopinavir and darunavir are
potent inhibitors of HIV-2 isolates [12].
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In the context of the large and still ongoing scale-up of
ART in the West African region, HIV-2 infection causes specific
operational, clinical and public health challenges [13]. First,
the lack of routinely available rapid antibody tests to dif-
ferentiate between HIV-1 and HIV-2 can lead to delayed
diagnoses and thus to initiation of inappropriate and ineffec-
tive first-line ART prescriptions [14,15]. Indeed, a previous
study of our group [15] showed that despite international
recommendations 17% of HIV-2-infected patients were initi-
ally treated with inappropriate NNRTI-containing regimens,
resulting in poor immunological response mainly due to late
confirmation of HIV-2 infection [15]. Second, the lack of
commercial viral load quantification assay [16] impacts on the
monitoring of HIV-2 infected patients [13,17].
Owing to its low prevalence and its geographical restriction
to West Africa, response to ART in HIV-2 infection is still
poorly understood [4,18]. There have been no randomized
trials investigating the response to ART regimens in HIV-2-
infected patients [19]. Only a few observational cohort studies
with limited sample size have provided information on HIV-2-
infected patients on ART in Europe and in the United States
[2026], as well as in West Africa [1315, 2731]. Moreover,
limited data are available on the response to the different
first-line regimens used in HIV-2 patients.
Whereas the data have generally favoured boosted PI
regimens over those comprised of triple NRTIs, to our know-
ledge, only one report from a European collaboration [20] and
two from West Africa [15,30] explicitly compared the two
first-line regimens. Using data from the International Epide-
miological Database to Evaluate AIDS West Africa (IeDEA-WA)
HIV-2 collaboration [32], we aimed to investigate the impact
of first-line ART regimens on immunological response within
the first 12 months of ART, for HIV-2 infected patients in
the West Africa region where there are limited options for
second-line regimens.
Methods
Description of the cohort
Since 2006 a network of adult and paediatric HIV clinics in
West Africa has existed as part of the global IeDEA Collabora-
tion (www.iedea.org/), funded by the US National Institutes
of Health [32]. The IeDEA-WA HIV-2 cohort was recently
established in order to better understand the epidemiology,
care patterns and treatment of HIV-2 infection [33]. This
cohort includes HIV-2 and dually HIV-1- and HIV-2-infected
patients, on ART or not, followed in 12 clinics located in five
West African countries (six in Coˆte d’Ivoire, two in Mali, two
in Burkina Faso, one in Benin and one in Senegal).
Data collection
Standardized questionnaires capturing the relevant infor-
mation on HIV-2 care were developed with an electronic
database implemented at the site level. All sites completed
the specific questionnaires retrospectively and then prospec-
tively and entered the data into the IeDEA-WA HIV-2 database.
The databases from each site are sent every six months to
the Regional Centre in Abidjan, Coˆte d’Ivoire, and Bordeaux,
France, using compression/encryption software. Data col-
lected include the following: 1) Baseline demographics and
clinical data: birth date, gender, HIV clinical stage (WHO or CDC
stage), ART initiated, clinical assessment, medical history;
2) Follow-up: clinical assessment (tuberculosis, other diseases/
infection, HIV clinical stage, weight, height, medications such
as antiretroviral drugs and co-trimoxazole); 3) Biological data:
CD4 count, haemoglobin, aspartate transaminase, alanine
transaminase and plasma HIV RNA viral load (when available);
4) Outcomes: death, loss to follow-up and transferred out.
Inclusion criteria
Patients aged 17 years at ART initiation and with an HIV-2
infection confirmed by two or three rapid HIV tests based
on country-specific national algorithms were eligible for this
analysis. Only those patients who initiated ART with three
NRTIs or a PI-based regimen were included. Patients without
documented CD4 count at ART initiation and/or with unknown
gender were excluded.
Antiretroviral treatment
ART was provided to the HIV-2 infected patients according
to the national guidelines. In West Africa, HIV-2 treatment
guidelines were based on WHO recommendations [34]. Up to
2013, the recommended first-line regimen contained three
NRTIs (tenofovir (TDF)lamivudine (3TC) or emtricitabine
(FTC)zidovudine (AZT) or AZT3TCabacavir (ABC)). Since
2013, a boosted PI-based regimen has been recommended,
with lopinavir being the preferred option. In patients for
whom boosting the PI is contraindicated or not tolerated,
a triple NRTI regimen was recommended (AZT3TC or
FTCTDF or ABC).
Follow-up and CD4 count measurement
After initiation into care, patients were typically followed up
every six months or were seen in between scheduled visits if
illness occurred. T-CD4 lymphocyte counts were measured
every six months. The absolute CD4/CD8 T-cell counts
were performed using standard flow cytometry (FACScan,
Becton Dickinson).
Statistical analysis
CD4 count trajectories over the first 12 months of ART were
modelled using linear mixed models (LMMs), with baseline
defined as the date of ART initiation. We included all CD4
count measurements between baseline (or the first CD4 count
recorded within a window of six months prior to baseline) and
24 months of follow-up (or six months later at the latest). In
the main analysis, patients who switched initial treatment
were right censored at the date of switching. We modelled
the CD4 count changes over time [35] using fractional
polynomials of one and two degrees with powers 2, 1,
0.5, 0 (natural log), 0.5, 1, 2 and 3.The best-fitting fractional
polynomial was selected by comparing the deviance of
different models and had powers 0.5 and 1. Random effects
on the different fractional polynomial terms accounted for the
correlation of repeated measurements within each subject.
For degree-2 models unstructured and diagonal covariance
matrices were compared. Models with an unstructured
covariance matrix were selected, as their Akaike information
criterion was smaller. Univariable LMMs were used to assess
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covariate effects, and a manual backwards selection method
was used to select significant variables in a multivariable
LMM. To confirm the adequacy of the model, residual homo-
scedasticity and normality were graphically checked.
To address possible informative dropout we performed a
sensitivity analysis restricted to patients remaining in care
beyond the 12 months of ART (patients deceased or lost to
follow-up were excluded). Patients were defined as lost to
follow-up if they were not known to have died, not known
to have transferred out and not seen at the clinic at least
once in the last six months prior to the closure date of the
database [36].
In a second sensitivity analysis, we performed the multi-
variable LMM in an intent-to-treat analysis.
Results
Selection of the study sample
As of March 2013 the IeDEA-WA database contained 2005
patients infected with HIV-2 (or dually infected with HIV-1
and HIV-2). Figure 1 shows the different steps of the selection
of the study sample. We excluded 590 HIV-2 patients and 344
dually infected patients because they were not treated with
ART. We excluded 485 patients because they were dually
infected, one patient with an unknown first-line ART regimen
and 44 (7.5%) HIV-2 patients treated with a non-recommended
first-line ART regimen. Among these 44 patients, 41 were
initially treated with an NNRTI-based regimen and three
with only two drugs. Of these 44 patients, 31 (70.5%) treated
with a non-recommended ART regimen had a subsequent
drug combination switch reported (28 (90.3%) switched to
a PI-based regimen and three patients (9.7%) switched to
a triple NRTI regimen), at a median 14 months after ART
initiation (interquartile range (IQR) 2.7 to 21.3 months). After
exclusion of 118 patients without documented baseline
CD4 count measurements, there remained 422 eligible HIV-
2-infected patients that initiated ART between 1999 and
2012 who constituted the core sample for this analysis.
Sample characteristics
Of 422 eligible patients, 285 (67.5%) started a boosted
PI-based ART regimen, 104 (24.6%) an unboosted PI-based
regimen and 33 (7.8%) a triple NRTI regimen (Table 1). The
subjects in the three groups had similar sex and age distri-
butions, mortality and loss to follow-up, but varied markedly
in their baseline clinical stage, baseline CD4 count, follow-
up duration and the calendar year of starting ART (Table 1).
Of the patients treated with a boosted or unboosted PI-based
regimen, 17% had an advanced clinical stage (WHO IV or CDC
C) compared to 21.2% of patients treated with three NRTIs
(p0.02). Baseline CD4 cell count was lower in the unboosted
PI group (median 129 cells/ml; 67 to 206) compared to the
boosted PI group (173 cells/ml; 80 to 265) and to the NRTI
group (192 cells/ml; 114 to 308; p0.003). Median follow-
up time was higher for the unboosted PI group (median
44 months; 13.2 to 72.0) compared to 17.7 months (2.4 to
36.6) and 12.9 months (0 to 38.9) for patients treated with
a boosted PI-based and a three-NRTI regimen, respectively
(pB0.001). Twenty-one (63.6%) patients initially treated with
three NRTIs started their first-line ART regimen between 2008
and 2012, compared to 191 (67.0%) patients treated with a
boosted PI-based regimen and 9 (8.6%) patients treated with
an unboosted PI-based regimen (pB0.001). Of the patients
treated with a PI-based regimen (boosted or not) 55% were
female, compared to 42.4% of the patients treated with three
NRTIs (p0.35). The median age at ART initiation was 45.5
(38.9 to 52.1), 44.2 (36.9 to 51.2) and 46.1 (40.7 to 51.9) years
for patients treated with a boosted PI-based, unboosted PI-
based and triple NRTI regimen, respectively (p0.59). Twelve
months after starting ART there were 12 (2.8%) deaths in
total, with similar proportions in the three treatment groups
(3.2%, 1.9% and 3.0% in the boosted PI, unboosted PI and
NRTI groups, respectively; p0.80). Twenty-four percent of
patients were lost to follow-up after 12 months (p0.43).
The triple NRTI ART combinations prescribed were AZT3TC
and ABC for 22 patients (66.7%), stavudine3TC and dida-
nosine for six patients (18.2%), stavudine3TC and ABC for
three patients (9.1%) and AZT3TC and didanosine for two
patients (6.1%). For patients treated with a boosted PI-based
regimen, the initial combinations mostly prescribed were
AZT3TC and lopinavir-ritonavir for 130 patients (45.6%),
stavudine3TC and lopinavir-ritonavir for 52 patients (18.3%)
and AZT3TCindinavir and ritonavir for 34 patients (11.9%).
For patients treated with an unboosted PI-based regimen,
the initial combinations mostly prescribed were AZT3TC
indinavir for 61 patients (58.7%), stavudine3TCindinavir for
25 patients (24.0%) and AZT3TCnelfinavir for 9 patients
(8.7%). Lopinavir-ritonavir was the most frequently prescribed
PI for 73.7% in the boosted PI group (n210), followed by
IeDEA West Africa HIV-2 cohort
March 2013
N=2,005 patients
934 patients excluded:
344 dually infected and 
590 HIV-2 infected 
who had not started ART
485 patients excluded:dually 
reactive HIV-1&2
N=1,071 patients on ART
N=586 HIV-2-infected patients on ART
41 treated with NNRTI-
based regimen
3 treated with dual therapy
1 with unknown regimen
N=541 HIV-2-infected patients 
treated with PI-based regimen
or three NRTIs
118 patients without 
baseline CD4 count 
available
1 patient with gender not 
documented
STUDY SAMPLE
N=422
Figure 1. Flow chart of the selection of the study sample of
patients infected only with HIV-2 and treated with a recommended
antiretroviral treatment regimen, IeDEA West Africa Collaboration.
ART, antiretroviral treatment; NNRTI, non-nucleoside reverse-tran-
scriptase inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse-
transcriptase inhibitors
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indinavir for 25.3% (n72) and saquinavir for three patients
(1.1%). In the unboosted PI group 88 (84.6%) patients were
treated with indinavir and 16 (15.4%) with nelfinavir.
Treatment modification during the first 12 months of
ART was reported for 11 (33.3%) patients initially treated
with three NRTIs: five patients switched to a boosted PI-based
regimen, four to another NRTI-based combination and two
to an NNRTI-based regimen. Of 45 (15.8%) patients initially
treated with a boosted PI-based regimen who had a treat-
ment modification within 12 months, 38 were still treated
with a boosted PI-based regimen, three were treated with
three NRTIs, two with a NNRTI combination, one with an
unboosted PI-based regimen and one with two NRTIs. Of 27
(26.0%) patients initially treated with an unboosted PI-based
regimen, 24 were treated with a boosted PI-based regimen,
two with an NNRTI combination and one with three NRTIs.
The median times from ART initiation to treatment modifica-
tion were 5.7 (2.9 to 8.9), 4.9 (2.8 to 8.7) and 5.8 (2.0 to 8.8)
months for patients initially treated with three-NRTI, un-
boosted PI-based and boosted PI-based regimens, respec-
tively. Reasons for ART modification were not recorded in
the database.
Immunologic response to ART treatment
Figure 2a shows trajectories of CD4 count recovery estimated
by the multivariable LMM stratified by CD4 count category
at baseline. In the reference group (women treated with
a boosted PI-based regimen and with an initial CD4 count
Table 1. Baseline characteristics of the HIV-2-infected patients on antiretroviral therapy (ART), IeDEA West Africa Collaboration
(n422)
Initial ART regimen
Unboosted PI-based
n104
Boosted PI-based
n285
Three NRTIs
n33 pa
Country (%) 0.003
Coˆte d’Ivoire 71 (25.8) 177 (64.4) 27 (9.8)
Burkina Faso 13 (15.8) 69 (84.2) 
Mali 12 (35.3) 21 (61.8) 1 (2.9)
Senegal 8 (27.6) 16 (55.2) 5 (17.2)
Benin  2 (100) 
Female (%) 58 (55.8) 158 (55.4) 14 (42.4) 0.348
Age (in years) median (IQR) 44.2 (36.9;51.2) 45.5 (38.9;52.1) 46.1 (40.7;51.9) 0.586
Baseline clinical stage (%) 0.020
WHO I/II or CDC A 12 (11.5) 64 (22.5) 4 (12.1)
WHO III or CDC B 63 (60.6) 128 (44.9) 13 (39.4)
WHO IV or AIDS 18 (17.3) 48 (16.8) 7 (21.2)
missing 11 (10.6) 45 (15.8) 9 (27.3)
Baseline haemoglobin (g/dl) median (IQR) 10.6 (9.6;11.9) 11.3 (9.8;12.5) 11.5 (10.2;12.3) 0.225
Baseline CD4 count (cells/ml) median (IQR) 129 (67;206) 173 (80;265) 192 (114;308) 0.003
Baseline CD4 count (%) 0.047
0 to 49 20 (19.2) 42 (14.7) 1 (3.0)
50 to 99 21 (20.2) 44 (15.4) 5 (15.2)
100 to 199 36 (34.6) 74 (26.0) 11 (33.3)
200 to 349 21 (20.2) 85 (29.8) 10 (30.3)
349 6 (5.8) 40 (14.0) 6 (18.2)
Year of ART initiation (%) B0.001
B2004 17 (16.4) 6 (2.1) 9 (27.3)
2004 to 2005 49 (47.1) 22 (7.7) 3 (9.1)
2006 to 2007 29 (27.9) 66 (23.2) 
2008 to 2009 7 (6.7) 100 (35.1) 11 (33.3)
2010 to 2012 2 (1.9) 91 (31.9) 10 (30.3)
Follow-up duration (months) median (IQR) 44.0 (13.2;72.0) 17.7 (2.4;36.6) 12.9 (0;38.9) B0.001
Deceased (%)b 2 (1.9) 9 (3.2) 1 (3.0) 0.800c
Lost to follow-up (%)b 20 (19.2) 73 (25.6) 8 (24.2) 0.426
IQR, interquartile range; PI, protease inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; WHO, World Health Organization;
achi-square test for qualitative variables and Kruskal-Wallis test for quantitative variables; bduring the first 12 months after ART initiation;
cFisher’s exact test.
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B50 cells/ml), the mean CD4 changes were 132 cells/ml
(95% CI 89 to 176) and 191 cells/ml (95% CI 142 to 241) at
6 and 12 months after starting ART, respectively. Table 2
shows estimated mean CD4 changes at 6 and 12 months
after starting ART. The CD4 count response to ART within
the first 12 months of ART was associated with the absolute
value of the baseline CD4 count (p0.0291), with gender
(p0.0302) and with the type of first ART regimen
(p0.0045). Compared to patients with a baseline CD4 count
B50 cells/ml, patients with baseline CD4 count ]350 had
lower CD4 count recovery (99 cells/ml (164 to 34))
12 months after ART initiation. Compared to women, men
had a lower CD4 count recovery after 12 months of ART
(39 cells/ml (71 to 8)). We found no association
between CD4 response to ART and age, baseline haemoglo-
binaemia, year of ART initiation, country and initial clinical
stage (data not shown).
There was a strong association between the type of first-
line ART regimen and the overall CD4 response trajectory
(p0.0045). Compared to patients initially treated with a
boosted PI-based regimen, CD4 count recovery was lower
for patients treated with three NRTIs or with an unboosted
PI-based regimen (72 cells/ml (129 to 16); 42 cells/ml
(74 to 10), respectively) at six months. The difference
in CD4 count recovery between the three treatment groups
persisted at 12 months (Figure 2b).
The results of the sensitivity analysis restricted to patients
remaining in care (n265) were similar to those from the
main analysis. CD4 count changes at 12 months estimated
from these two models, according to baseline CD4 count, are
shown in Figure 3.
The results of the second sensitivity intent-to-treat analysis
were similar to those from the main analysis.
Discussion
Based on a collaborative analysis of data combined from
12 clinics located in five West African countries, we described
immunological responses of HIV-2 infected patients in the
Figure 2. Mean adjusted CD4 count change after antiretroviral
treatment initiation according to baseline CD4 count (2a  top
panel) and by antiretroviral treatment regimen (2b  bottom
panel), IeDEA West Africa Collaboration.
Table 2. Mean CD4 count changes at 6 and 12 months compared to the reference groupa and estimated with multivariable linear
mixed model (N422; 1341 observations), IeDEA West Africa Collaboration
Variables
Mean CD4 change difference
(cells/ml) at 6 months (95% CI)
Mean CD4 change difference
(cells/ml) at 12 months (95% CI) p
Baseline CD4 count (cells/ml) 0.0291
B50 Referenceb Referencec
50 to 99 6 (59 to 48) 45 (105 to 16)
100 to 199 6 (53 to 41) 29 (83 to 24)
200 to 349 18 (66 to 29) 49 (104 to 5)
]350 59 (116 to 1) 99 (164 to 34)
Gender 0.0302
Female Referenceb Referencec
Male 26 (54 to 2) 39 (71 to 8)
First ART regimen 0.0045
Boosted PI-based Referenceb Referencec
Unboosted PI-based 42 (74 to 10) 58 (94 to 23)
NRTI-based 72 (129 to 16) 81 (148 to 14)
aFemales with initial CD4 count B50 cells/ml treated with boosted PI-based regimen; CI, confidence interval; ART, antiretroviral treatment;
PI, protease inhibitor; NRTI, nucleoside reverse-transcriptase inhibitors; bthe mean CD4 count change for the reference group at 6 months was
132 cells/ml (95% CI89; 176); cthe mean CD4 count change for the reference group at 12 months was 191 cells/ml (95% CI142; 241).
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largest sample of HIV-2-infected patients followed for up to
12 months on ART. We compared the ART regimens re-
commended by the WHO for low- and middle-income settings
and found CD4 count responses to be higher for patients
treated with boosted PI-based regimens than for those
treated with triple NRTI or unboosted PI-based regimens 6
and 12 months after ART initiation.
Another study that investigated the immunological re-
sponses to the two first-line ART regimens for HIV-2 infected
patients, the European cohort study ACHIEV2E [20], showed a
lower immunological response for patients initially treated
with three NRTIs than those treated with a PI-based regimen.
Indeed, a CD4 count decrease was observed for patients
treated with three NRTIs (60 cells/ml per year) and a CD4
count increase for those treated with a PI-based regimen
(76 cells/ml per year). At 12 months, the CD4 counts for
patients treated with three NRTIs and a PI-based regimen
were 191 and 327 cells/ml, respectively. The immunological
response beyond month 12 was not investigated in that
study. Whether the early immunological advantage observed
with boosted PI-based ART translates into clinical bene-
fits cannot be answered here and will be difficult to
investigate.
In light of the results of the European cohort study [20],
in 2013 a French group of experts [37] recommended the use
of a PI-based regimen as a first-line combination and ceased
to recommend the use of a triple NRTI-based regimen for
HIV-2 infected patients. The choice between the two first-line
regimens is probably more critical in low-income countries:
On the one hand, therapies based on a combination of three
NRTIs are an interesting alternative in a context of high
tuberculosis prevalence because treatment with a rifampin-
based regimen requires double boosting of ritonavir in associa-
tion with lopinavir or saquinavir, which results in an increased
risk of hepatotoxicity [38]. On the other hand, the risk of
occurrence of drug resistance has to be balanced against
this as there are limited options for second-line regimens. We
recently reported that, after a median duration of four years on
PI-based regimens, 74% of 145 HIV-2-infected patients had
suppressed viral loads of B50 copies/ml; however, HIV-2
resistance mutations to NRTIs and PIs were detected in 21 of
25 (84%) and 20 of 29 (69%) samples, respectively, despite
adequate antiretroviral plasma concentrations [39]. This study
clearly showed that in cases of virological failure there is a
limited HIV-2 therapeutic arsenal and that cross-resistance
dramatically reduced second-line treatment options. Another
study reported that 40% of patients with PI resistance
mutations appeared to be resistant to darunavir, which is
recommended as second-line therapy for HIV-2 patients [40].
With regard to the HIV-2 therapeutic arsenal, in cases of NRTI
and PI resistance, the only active drug class is integrase
inhibitors and possibly the CCR5 inhibitor maraviroc. However,
the use of integrase inhibitors may be limited in pretreated
patients who require a combination with fully active drugs and
who harbour NRTI-resistant viruses because of the low genetic
barrier to resistance of this drug class. The potential use
of integrase inhibitors and maraviroc is also limited by the
high costs of these medicines.
Among patients who initiated triple NRTI regimens, one-
third had changed treatment over the period of 12 months.
This rate was higher compared to other African public health
ART programmes treating HIV-1 patients and needs further
exploration to understand the reasons for treatment mod-
ification among HIV-2 patients. The most obvious explanation
for the high switch rate is the known inferiority of triple NRTI
regimens and co-treatment of tuberculosis being the main
reason for their use. Side effects, tolerability or adherence
could not be investigated as they were not available in our
database. In the European HIV-2 cohort study, treatment
modification was less common with switching reported in 12%
of patients in the PI group and 18% in the NRTI group [20].
A limitation of our study was the small number and limited
follow-up duration of HIV-2 infected patients treated with
three NRTIs (17 of the 33 patients had at least one CD4 count
documented after six months). Indeed, in the WHO guide-
lines of 2010 [8] this ART regimen was only recommended for
patients with a CD4 cell count 200 cells/ml. In the 2013
WHO consolidated guidelines [9] this eligibility criteria has
been dropped, which could lead to triple NRTI regimens
being prescribed more widely.
Another limitation is the use of suboptimal triple NRTI
regimens in West Africa. Some combinations used in this
study, such as AZT3TCABC, are not well tolerated and
are known to be less potent than triple NRTI regimens used
elsewhere in Africa.
Because the three groups of patients compared in our study
differed in terms of baseline CD4 count, baseline clinical stage
and follow-up duration, this analysis was possibly affected by
selection bias and the results should be interpreted with
caution, as in all observational cohorts comparing treatment
regimens [41]. In resource-limited countries, high rates of
patients lost to follow-up are frequently observed [42,43],
which could induce informative dropout [44]. However the
results of the sensitivity analysis we conducted on patients
remaining in care were similar to those of the main analysis,
showing that this informative dropout bias was limited.
Figure 3. Adjusted mean CD4 count change at M12 (cells/ml) with
95% confidence interval, by baseline CD4 count (cells/ml) for the
reference group (female treated by a first-line antiretroviral
treatment regimen including a boosted protease inhibitor). Estima-
tion by multivariable linear mixed model for patients remaining in
care (n265) and for all patients (n422), IeDEA West Africa
Collaboration.
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In conclusion this study further demonstrates the inferiority
of unboosted indinavir and triple nucleoside regimens for
the treatment of HIV-2 infection. Limitations inherent in
this observational design will be addressed by the First-Line
Treatment for HIV-2 trial (FIT-2, NCT02150993) already under-
way in five countries in West Africa and funded by the Agence
Nationale de Recherches sur le Sida et les he´patites virales
(ANRS). The critical issue of second-line regimens for HIV-2,
including the optimal sequence of integrase inhibitors and/
or boosted PIs, could potentially be addressed by a study
enrolling the subjects failing therapy in those two arms of
the FIT-2 trial.
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Appendix
The International Epidemiological Database to Evaluate AIDS
 West Africa Collaboration Study Group (as of January 2014)
Participating sites (*members of the Steering Committee,
§members of the Executive Committee)
Cotonou, Benin
Adults: Djimon Marcel Zannou*, Carin Ahouada, Jocelyn
Akakpo, Christelle Ahomadegbe´, Jules Bashi, Alice Gougounon-
Houe´to, Ange`le Azon-Kouanou, Fabien Houngbe´, Jean Sehonou
(CNHU Hubert Maga).
Paediatrics: Sikiratou Koumakpaı¨*§, Florence Alihonou,
Marcelline d’Almeida, Irvine Hodonou, Ghislaine Hounhoui,
Gracien Sagbo, Leı¨la Tossa-Bagnan, Herman Adjide (CNHU
Hubert Maga).
Burkina Faso
Adults: Joseph Drabo*, Rene´ Bognounou, Arnaud Diendere´,
Eliezer Traore, Lassane Zoungrana, Be´atrice Zerbo (CHU
Yalgado, Ouagadougou), Adrien Bruno Sawadogo*§, Jacques
Zoungrana, Arse`ne He´ma, Ibrahim Sore´, Guillaume Bado,
Achille Tapsoba (CHU Souro Sanou, Bobo-Dioulasso)
Paediatrics: Diarra Ye´*, Fla Koue´ta, Sylvie Ouedraogo,
Rasmata Oue´draogo, William Hiembo, Mady Gansonre´ (CH
Charles de Gaulle, Ouagadougou).
Abidjan, Coˆte d’Ivoire
Adults: Euge`ne Messou*, Joachim Charles Gnokoro, Mamadou
Kone´, Guillaume Martial Kouakou, (ACONDA-CePReF);
Clarisse Amani Bosse*, Kouakou Brou, Achi Isidore Assi
(ACONDA-MTCT-Plus); Henri Chenal*, Denise Hawerlander,
Franck Soppi (CIRBA); Albert Minga*, Yao Abo, Jean-Michel
Yoboue (CMSDS/CNTS); Serge Paul Eholie´*§, Mensah Deborah
Noelly Amego, Viviane Andavi, Zelica Diallo, Fre´de´ric Ello,
Aristophane Koffi Tanon (SMIT, CHU de Treichville), Serge
Olivier Koule*, Koffi Charles Anzan, Calixte Guehi (USAC, CHU
de Treichville).
Paediatrics: Edmond Addi Aka*, Koffi Ladji Issouf, Jean-Claude
Kouakou, Marie-Sylvie N’Gbeche, (ACONDA-CePReF); Toure´
Pety*, Divine Avit-Edi (ACONDA-MTCT-Plus); Kouadio Kouakou*,
Magloire Moh, Vale´rie Andoble´ Yao (CIRBA); Madeleine
Amorissani Folquet*, Marie-Evelyne Dainguy, Cyrille Kouakou,
Ve´ronique Tanoh Me´a-Assande, Gladys Oka-Berete, Nathalie
Zobo, Patrick Acquah, Marie-Berthe Kokora (CHU Cocody);
Tanoh Franc¸ois Eboua*, Marguerite Timite´-Konan, Lucre`ce
Diecket Ahoussou, Julie Kebe´ Assouan, Mabe´a Flora Sami,
Cle´mence Kouadio (CHU Yopougon).
Accra, Ghana
Paediatrics: Lorna Renner*§, Bamenla Goka, Jennifer Welbeck,
Adziri Sackey, Seth Ntiri Owiafe (Korle Bu TH).
Guinea-Bissau
Adults: Christian Wejse*§, Zacarias Jose´ Da Silva*, Joao Paulo
(Bandim Health Project); The Bissau HIV cohort study group:
Amabelia Rodrigues (Bandim Health Project), David da Silva
(National HIV Programme Bissau), Candida Medina (Hospital
National Simao Mendes, Bissau), Ines Oliviera-Souto (Bandim
Health Project), Lars Østergaard (Department of Infectious
Diseases, Aarhus University Hospital), Alex Laursen (Depart-
ment of Infectious Diseases, Aarhus University Hospital),
Morten Sodemann (Department of Infectious Diseases, Odense
University Hospital), Peter Aaby (Bandim Health Project),
Anders Fomsgaard (Department of Virology, Statens Serum
Institut, Copenhagen), Christian Erikstrup (Department of
Clinical Immunology), Jesper Eugen-Olsen (Department of
Infectious Diseases, Hvidovre Hospital, Copenhagen).
Bamako, Mali
Adults: Moussa Y Maı¨ga*§, Fatoumata Fofana Diakite´,
Abdoulaye Kalle, Drissa Katile (CH Gabriel Toure), Hamar
Alassane Traore*, Daouda Minta*, Tidiani Cisse´, Mamadou
Dembele´, Mohammed Doumbia, Mahamadou Fomba,
Asse´tou Soukho Kaya, Abdoulaye M Traore´, Hamady Traore´,
Amadou Abathina Toure (CH Point G).
Paediatrics: Fatoumata Dicko*, Mariam Sylla, Alima Berthe´,
Hadizatou Coulibaly Traore´, Anta Koı¨ta, Niaboula Kone´,
Cle´mentine N’Diaye, Safiatou Toure´ Coulibaly, Mamadou
Traore´, Naı¨chata Traore´ (CH Gabriel Toure).
Nigeria
Adults: Man Charurat* (UMB/IHV), Vivian Kwaghe*, Samuel
Ajayi, Georgina Alim, Stephen Dapiap, Otu (UATH, Abuja),
Festus Igbinoba (National Hospital Abuja), Okwara Benson*,
Cle´ment Adebamowo*, Jesse James, Obaseki, Philip Osakede
(UBTH, BeninCity), John Olasode (OATH, Ile-Ife).
Dakar, Senegal
Adults: Moussa Seydi*, Papa Salif Sow, Bernard Diop, Noe¨l
Magloire Manga, Judicael Malick Tine§, Coumba Cisse´ Bassabi
(SMIT, CHU Fann).
Paediatrics: Haby Signate Sy*, Abou Ba, Aida Diagne, He´le`ne
Dior, Malick Faye, Ramatoulaye Diagne Gueye, Aminata Diack
Mbaye (CH Albert Royer).
Lome´, Togo
Adults: Akessiwe Patassi*, Awe`rou Kotosso, Benjamin Goilibe
Kariyare, Gafarou Gbadamassi, Agbo Komi, Kankoe´ Edem
Mensah-Zukong, Pinuwe Pakpame (CHU Tokoin/Sylvanus
Olympio).
Paediatrics: Koko Lawson-Evi*§, Yawo Atakouma, Elom Takassi,
Ame´yo Djeha, Ayoko Ephoe´vi-gah, Sherifa El-Hadj Djibril (CHU
Tokoin/Sylvanus Olympio).
Executive Committee*: Franc¸ois Dabis (Principal Investiga-
tor, Bordeaux, France), Emmanuel Bissagnene (Co-Principal
Investigator, Abidjan, Coˆte d’Ivoire), Elise Arrive´ (Bordeaux,
France), Patrick Coffie (Abidjan, Coˆte d’Ivoire), Didier
Ekouevi (Abidjan, Coˆte d’Ivoire), Antoine Jaquet (Bordeaux,
France), Vale´riane Leroy (Bordeaux, France), Charlotte Lewden
(Bordeaux, France), Annie J Sasco (Bordeaux, France).
Operational and Statistical Team: Jean-Claude Azani
(Abidjan, Coˆte d’Ivoire), Eric Balestre (Bordeaux, France), Serge
Bessekon (Abidjan, Coˆte d’Ivoire), Sophie Karcher (Bordeaux,
France), Jules Mahan Gonsan (Abidjan, Coˆte d’Ivoire), Je´roˆme
Le Carrou (Bordeaux, France), Se´verin Lenaud (Abidjan,
Coˆte d’Ivoire), Ce´lestin Nchot (Abidjan, Coˆte d’Ivoire), Karen
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Malateste (Bordeaux, France), AmonRoseamonde Yao (Abidjan,
Coˆte d’Ivoire).
Administrative Team: Abdoulaye Cisse´ (Abidjan, Coˆte
d’Ivoire), Alexandra Doring§ (Bordeaux, France), Adrienne
Kouakou (Abidjan, Coˆte d’Ivoire), Guy Gneppa (Abidjan, Coˆte
d’Ivoire), Elodie Rabourdin (Bordeaux, France), Jean Rivenc
(Pessac, France).
Consultants/Working Groups: Xavier Anglaret (Bordeaux,
France), Boubacar Ba (Bamako, Mali), Renaud Becquet
(Bordeaux, France), Juan Burgos Soto (Bordeaux, France),
Jean Bosco Essanin (Abidjan), Andrea Ciaranello (Boston,
MA, USA), Se´bastien Datte´ (Abidjan, Coˆte d’Ivoire), Sophie
Desmonde (Bordeaux, France), Jean-Serge Elvis Diby (Abidjan,
Coˆte d’Ivoire), Geoffrey S.Gottlieb* (Seattle, WA, USA),
Apollinaire Gninlgninrin Horo (Abidjan, Coˆte d’Ivoire), Julie
Jesson (Bordeaux, France), Serge N’zore´ Kangah (Abidjan,
Coˆte d’Ivoire), David Meless (Abidjan, Coˆte d’Ivoire), Aida
Mounkaila-Harouna (Bordeaux, France), Camille Ndondoki
(Bordeaux, France), Caroline Shiboski (San Francisco, CA,
USA), Boris Tchounga (Abidjan, Coˆte d’Ivoire), Rodolphe
Thie´baut (Bordeaux, France), GillesWandeler (Dakar, Senegal).
Funding: The National Cancer Institute, the Eunice Kennedy
Shriver National Institute of Child Health and Human Develop-
ment and the National Institute of Allergy and Infectious
Diseases of the US National Institutes of Health, as part of
the International Epidemiologic Databases to Evaluate
AIDS (IeDEA) under award number U01AI069919. The content
is solely the responsibility of the authors and does not
necessarily represent the official views of the National
Institutes of Health.
Coordinating Centre: ISPED, Univ Bordeaux Segalen, Bordeaux,
France
Regional Office: PAC-CI, Abidjan, Coˆte d’Ivoire
Methodologic Support: MEREVA, Bordeaux, France
Website: http://www.mereva.net/iedea
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